INTERPHEX 2014: New Partners, New Programs - Conference programming from PDA and BioPharm International expand educational opportunities at Interphex 2014. - BioPharm International

ADVERTISEMENT

INTERPHEX 2014: New Partners, New Programs
Conference programming from PDA and BioPharm International expand educational opportunities at Interphex 2014.


BioPharm International
Volume 27, Issue 3, pp. 6

In the summer of 2013, INTERPHEX representatives hit the road, visiting customers and gathering insight on how we could continue to evolve INTERPHEX (International Pharmaceutical Expo) to meet the needs of the industry. We have listened and have taken action with the support of our exhibitors, partners, and loyal attendees.

INTERPHEX is the industry’s source for complete bio/pharmaceutical manufacturing solutions for manufacturers to confidently process, fill, and finish life-enhancing drugs. Attendees can touch and procure the latest technology from more than 650 of the industry’s best vendors, many displaying new equipment products, alongside service providers offering new capabilities.

This year INTERPHEX is going beyond the show floor and giving attendees the knowledge that they asked for with a new conference program produced by Parenteral Drug Association (PDA) and new programs that support all dosage forms.

INTERPHEX is partnering with the PDA, a global provider of science, technology, and regulatory information and education to the pharmaceutical and biopharmaceutical community, which allows us to deliver opportunities for knowledge, interaction, and professional growth for show attendees. PDA’s Education @INTERPHEX provides comprehensive, commercial-free, and objective discussions on the latest industry trends and thinking from thought leaders and regulators in the pharmaceutical and biopharmaceutical industry including headline speaker Richard Friedman, associate director, Office of Manufacturing and Product, Center for Drug Evaluation and Research, FDA.

We’ve also added additional complimentary programs to help attendees keep up with current trends and learn technical and practical experiences, including: case studies, CRB Tech Tank Series, IPS Technologies Floor Tours, Innovation Stages, specialty forums, workshops, and a special Student and Young Professionals Program.

These educational programs will address the needs of the industry focusing on: biologics development, parenteral dosage forms; oral solid dosage forms; facility architecture; regulatory and compliance issues; facility management, expansion, construction, and capital investment; and managing the supply chain.

BioPharm International and Pharmaceutical Technology will host a Specialty Forum plus eight sessions in the Innovation Center on the Exhibit Hall show floor. The Innovation Stage lineup for Tuesday, March 18 features sessions on High-Potency Manufacturing for Finished Drugs and Implementing Effective Cleaning Validation Programs, as well as Advances in Hot-Melt Extrusion Manufacturing, Continuous Manufacturing for Solid Dose Drugs.

Wednesday, March 19 will begin with a Specialty Forum, the annual State of CMO Industry 2014, presented by Jim Miller, president of PharmSource Information Services. Innovation Stage presentations slated for March 19 are Track and Trace/Serialization, Quality and Contract Manufacturing, Continuous Manufacturing for Biologic Drugs, and Modular Biopharmaceutical Manufacturing Systems. See the complete schedule at www.INTERPHEX.com.

With the combination of more than 650 leading suppliers, long-time industry partnerships, the new PDA partnership, and new special program offerings, INTERPHEX 2014 promises to be its best show ever!

Receive a complimentary exhibit hall pass when you register at www.INTERPHEX.com/PharmTech.

As always, we’d love to hear from you, please contact us.

RJ Palermo
RJ Palermo

Abou the Author
RJ Palermo is vice-president of INTERPHEX, rpalermo@reedexpo.com.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here